PMC:7755033 / 74300-74487 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7755033","sourcedb":"PMC","sourceid":"7755033","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7755033","text":"12.5. Best docking poses of WS phytoconstituents with SARS-CoV main protease/3CL-pro (PBB ID: 1P9U) in comparison to the FDA approved standard reference drugs (Oberadilol and Poziotinib)\n","tracks":[{"project":"LitCovid-sentences","denotations":[{"id":"T703","span":{"begin":0,"end":5},"obj":"Sentence"},{"id":"T704","span":{"begin":6,"end":93},"obj":"Sentence"},{"id":"T705","span":{"begin":94,"end":186},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T703","pred":"source","obj":"LitCovid-sentences"},{"subj":"T704","pred":"source","obj":"LitCovid-sentences"},{"subj":"T705","pred":"source","obj":"LitCovid-sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-sentences","color":"#93ec9d","default":true}]}]}}